AAPL   378.85 (+1.65%)
MSFT   210.81 (+1.23%)
FB   240.14 (-0.30%)
GOOGL   1,498.33 (+0.56%)
NVDA   400.49 (+1.42%)
CGC   16.51 (+0.06%)
BABA   246.44 (+4.20%)
MU   49.36 (+0.55%)
GE   6.83 (+1.04%)
AMD   52.76 (-0.32%)
T   30.39 (+0.23%)
ACB   12.32 (-0.81%)
F   6.12 (+0.00%)
GILD   76.24 (-0.24%)
DIS   114.08 (+0.40%)
BAC   22.97 (-0.17%)
NFLX   498.74 (+1.13%)
BA   178.02 (-0.48%)
AAPL   378.85 (+1.65%)
MSFT   210.81 (+1.23%)
FB   240.14 (-0.30%)
GOOGL   1,498.33 (+0.56%)
NVDA   400.49 (+1.42%)
CGC   16.51 (+0.06%)
BABA   246.44 (+4.20%)
MU   49.36 (+0.55%)
GE   6.83 (+1.04%)
AMD   52.76 (-0.32%)
T   30.39 (+0.23%)
ACB   12.32 (-0.81%)
F   6.12 (+0.00%)
GILD   76.24 (-0.24%)
DIS   114.08 (+0.40%)
BAC   22.97 (-0.17%)
NFLX   498.74 (+1.13%)
BA   178.02 (-0.48%)
AAPL   378.85 (+1.65%)
MSFT   210.81 (+1.23%)
FB   240.14 (-0.30%)
GOOGL   1,498.33 (+0.56%)
NVDA   400.49 (+1.42%)
CGC   16.51 (+0.06%)
BABA   246.44 (+4.20%)
MU   49.36 (+0.55%)
GE   6.83 (+1.04%)
AMD   52.76 (-0.32%)
T   30.39 (+0.23%)
ACB   12.32 (-0.81%)
F   6.12 (+0.00%)
GILD   76.24 (-0.24%)
DIS   114.08 (+0.40%)
BAC   22.97 (-0.17%)
NFLX   498.74 (+1.13%)
BA   178.02 (-0.48%)
AAPL   378.85 (+1.65%)
MSFT   210.81 (+1.23%)
FB   240.14 (-0.30%)
GOOGL   1,498.33 (+0.56%)
NVDA   400.49 (+1.42%)
CGC   16.51 (+0.06%)
BABA   246.44 (+4.20%)
MU   49.36 (+0.55%)
GE   6.83 (+1.04%)
AMD   52.76 (-0.32%)
T   30.39 (+0.23%)
ACB   12.32 (-0.81%)
F   6.12 (+0.00%)
GILD   76.24 (-0.24%)
DIS   114.08 (+0.40%)
BAC   22.97 (-0.17%)
NFLX   498.74 (+1.13%)
BA   178.02 (-0.48%)
Log in

NASDAQ:DRNADicerna Pharmaceuticals Stock Price, Forecast & News

$25.48
-0.26 (-1.01 %)
(As of 07/8/2020 09:31 AM ET)
Add
Compare
Today's Range
$25.46
Now: $25.48
$25.74
50-Day Range
$19.56
MA: $22.74
$26.62
52-Week Range
$11.75
Now: $25.48
$27.68
Volume6,526 shs
Average Volume789,968 shs
Market Capitalization$1.88 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.82
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. Its principal development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and a program for an undisclosed rare liver disease. The company's development programs also comprise additional rare disease programs; a program for the treatment of hypercholesterolemia; and various programs in various therapeutic areas involving liver function. The company has strategic collaborations with Eli Lilly and Company, Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.
Read More
Dicerna Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.70 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DRNA
CUSIPN/A
Phone617-621-8097

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$23.90 million
Book Value$2.22 per share

Profitability

Net Income$-120,460,000.00
Net Margins-213.04%

Miscellaneous

Employees78
Market Cap$1.88 billion
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive DRNA News and Ratings via Email

Sign-up to receive the latest news and ratings for DRNA and its competitors with MarketBeat's FREE daily newsletter.

Dicerna Pharmaceuticals (NASDAQ:DRNA) Frequently Asked Questions

How has Dicerna Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Dicerna Pharmaceuticals' stock was trading at $16.88 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, DRNA stock has increased by 50.9% and is now trading at $25.48. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Dicerna Pharmaceuticals?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dicerna Pharmaceuticals in the last year. There are currently 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Dicerna Pharmaceuticals.

When is Dicerna Pharmaceuticals' next earnings date?

Dicerna Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Dicerna Pharmaceuticals.

How were Dicerna Pharmaceuticals' earnings last quarter?

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) issued its earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the Zacks' consensus estimate of $0.28 by $0.59. The biopharmaceutical company earned $34.03 million during the quarter, compared to analyst estimates of $59.61 million. Dicerna Pharmaceuticals had a negative net margin of 213.04% and a negative return on equity of 74.79%. View Dicerna Pharmaceuticals' earnings history.

What price target have analysts set for DRNA?

11 equities research analysts have issued 12 month target prices for Dicerna Pharmaceuticals' stock. Their forecasts range from $25.00 to $50.00. On average, they anticipate Dicerna Pharmaceuticals' stock price to reach $34.20 in the next twelve months. This suggests a possible upside of 34.2% from the stock's current price. View analysts' price targets for Dicerna Pharmaceuticals.

Has Dicerna Pharmaceuticals been receiving favorable news coverage?

Media headlines about DRNA stock have been trending negative on Wednesday, according to InfoTrie Sentiment. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Dicerna Pharmaceuticals earned a news sentiment score of -2.1 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news about Dicerna Pharmaceuticals.

Are investors shorting Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals saw a drop in short interest in June. As of June 30th, there was short interest totaling 2,960,000 shares, a drop of 7.8% from the June 15th total of 3,210,000 shares. Based on an average daily trading volume, of 639,600 shares, the short-interest ratio is currently 4.6 days. Currently, 4.6% of the company's shares are short sold. View Dicerna Pharmaceuticals' Current Options Chain.

Who are some of Dicerna Pharmaceuticals' key competitors?

What other stocks do shareholders of Dicerna Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Amarin (AMRN), Strongbridge Biopharma (SBBP), Arbutus Biopharma (ABUS), TG Therapeutics (TGTX), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Exelixis (EXEL), ImmunoGen (IMGN) and Array Biopharma (ARRY).

Who are Dicerna Pharmaceuticals' key executives?

Dicerna Pharmaceuticals' management team includes the following people:
  • Dr. Douglas M. Fambrough III, Co-Founder, CEO, Pres & Director (Age 50)
  • Dr. Bob D. Brown, Chief Scientific Officer & Sr. VP (Age 54)
  • Dr. Ralf H. Rosskamp, Chief Medical Officer (Age 66)
  • Dr. Mark Behlke, Co-Founder & Member of Scientific Advisory Board
  • Prof. John J. Rossi, Co-Founder & Chairman of Scientific Advisory Board (Age 72)

What is Dicerna Pharmaceuticals' stock symbol?

Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."

How do I buy shares of Dicerna Pharmaceuticals?

Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Dicerna Pharmaceuticals' stock price today?

One share of DRNA stock can currently be purchased for approximately $25.48.

How big of a company is Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals has a market capitalization of $1.88 billion and generates $23.90 million in revenue each year. The biopharmaceutical company earns $-120,460,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. Dicerna Pharmaceuticals employs 78 workers across the globe.

What is Dicerna Pharmaceuticals' official website?

The official website for Dicerna Pharmaceuticals is www.dicerna.com.

How can I contact Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals' mailing address is 33 HAYDEN AVENUE, LEXINGTON MA, 02421. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected]

This page was last updated on 7/8/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.